PolySciTech (www.polyscitech.com) provides a wide array of block
copolymers and reactive intermediates including mPEG-PLGA and maleimide-PEG-PLGA
copolymers. A recent article from Albany College utilized these polymers to
generate a targeted nanoparticle carrier for delivery of toremifene to prostate
cancer. Read more: Hariri, Waseem, Thangirala Sudha, Dhruba J. Bharali, Huadong
Cui, and Shaker A. Mousa. "Nano-Targeted Delivery of Toremifene, an
Estrogen Receptor-α Blocker in Prostate Cancer." Pharmaceutical Research
(2015): 1-11. http://link.springer.com/article/10.1007/s11095-015-1662-x
“ABSTRACT: Purpose:
Estrogen Receptor-α (ERα) expression is increased in prostate cancer and acts
as an oncogene. We propose that blocking of estrogen hormone binding to ERα
using the ERα blocker toremifene will reduce the tumorigenicity of prostate
cancer, and nano-targeted delivery of toremifene will improve anticancer
efficacy. We report the synthesis and use in an orthotopic mouse model of
PLGA-PEG nanoparticles encapsulating toremifene and nanoparticles encapsulating
toremifene that are also conjugated to anti-PSMA for targeted prostate tumor delivery.
Methods: Human prostate cancer cell line PC3M and a nude mouse model were used
to test efficacy of nano-targeted and nano-encapsulated toremifene versus free
toremifene on the growth and differentiation of tumor cells. Results: Treatment
with free toremifene resulted in a significant reduction in growth of prostate
tumor and proliferation, and its nano-targeting resulted in greater reduction
of prostate tumor growth, greater toremifene tumor uptake, and enhanced tumor
necrosis. Tumors from animals treated with nano-encapsulated toremifene
conjugated with anti-PSMA showed about a 15-fold increase of toremifene
compared to free toremifene. Conclusions: Our data provide evidence that
blocking ERα by toremifene and targeting prostate cancer tissues with anti-PSMA
antibody on the nanoparticles’ surface repressed the tumorigenicity of prostate
cancer cells in this mouse model.”
No comments:
Post a Comment